Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TROP2 antibody-drug conjugate BIO-106

An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) linked to an as of yet undisclosed tubulin inhibitor, with potential antineoplastic activity. Upon administration of anti-TROP2 ADC BIO-106, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon binding and internalization, the tubulin inhibitor is released, and binds to tubulin and inhibits its polymerization. This results in G2/M phase arrest and apoptosis, and inhibits the proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TROP2 ADC BIO-106
Code name:BIO 106
BIO-106
BIO106
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search